We further demonstrated that daraxonrasib inhibition of osteosarcoma depended on the ratio of the active form of KRAS, as demonstrated by the increased daraxonrasib sensitivity of HOS cells that was induced by knockdown of RASA1. The gene discussed is KRAS; the disease is osteosarcoma.